WC
ACET icon

Wexford Capital’s Adicet Bio ACET Stock Holding History

Wexford Capital’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-933
Closed -$28.2K – 208
2023
Q4 		$28.2K Buy
+933
New +$20.3K 0.01% 166

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wexford Capital's ACET Position: Q1 2024 in Review

Wexford Capital sold out of Adicet Bio (ACET) in Q1 2024, closing a stake of 933 shares — an estimated $28.2K sold.

Wexford Capital first reported a position in ACET in Q4 2023 and held it in 1 quarter. The position peaked at $28.2K in Q4 2023. 96 funds tracked by Wall St. Rank hold ACET as of Q1 2024.

  • Wexford Capital reported no remaining Adicet Bio position as of Q1 2024 after selling out during the quarter.
  • Wexford Capital sold 933 Adicet Bio shares in Q1 2024, an estimated $28.2K.
  • Wexford Capital first reported a position in Adicet Bio in Q4 2023 and held it in 1 quarter.
  • Wexford Capital's Adicet Bio position peaked at $28.2K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.